EVALUATION OF CLINICAL AND PATHOLOGICAL FINDINGS AND TREATMENT OUTCOMES OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTRE EXPERIENCE

Objective: Renal involvement in systemic lupus erythematosus (SLE), also known as lupus nephritis (LN), leads to a worse prognosis than SLE without kidney involvement.Material and Methods: Biopsy-proven LN patients diagnosed between January 2012 and January 2021 were reviewed. Complete remission (CR...

Full description

Saved in:
Bibliographic Details
Main Authors: Batunay Duran, Ömer Faruk Akçay, Arzu Sağlam, Ebru Gök Oğuz, Mehmet Deniz Aylı
Format: Article
Language:English
Published: Istanbul University Press 2025-01-01
Series:İstanbul Tıp Fakültesi Dergisi
Subjects:
Online Access:https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/09F722444B614B0C828645B7A3E249A4
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Renal involvement in systemic lupus erythematosus (SLE), also known as lupus nephritis (LN), leads to a worse prognosis than SLE without kidney involvement.Material and Methods: Biopsy-proven LN patients diagnosed between January 2012 and January 2021 were reviewed. Complete remission (CR) was defined as a reduction in the urinary protein-to-creatinine ratio (UPCR) below 0.50 g/g. Partial response is characterised by a 24-h urine protein excretion reduction to below 3 g/day with at least a 50% decrease in proteinuria. Primary effective renal response was defined as PCR of less than 0.7 g/g and the absence of any rescue therapy for treatment failure.Result: All patients exhibited proteinuria at diagnosis, with class IV LN being the most common (36.4%) form, and 65.9% had prolif erative LN. At 12 months, CR was achieved in 16 patients (37.2%) with significant differences in systolic and diastolic blood pressure and eGFR at diagnosis (p=0.01, p=0.02, and p=0.016, respective ly). CR rates were lower at 12 months in patients with proliferative LN (p=0.024) and interstitial inflammation (p=0.04). Besides, no significant difference was found in CR rates at 6 and 12 months between PLN patients treated initially with steroids and cyclo phosphamide and those treated with steroids and mycopheno late mofetil (p>0.05). However, the median time to achieve CR was shorter in the mycophenolate mofetil group (p=0.048).Conclusion: LN remains a significant source of morbidity and mortality in patients with SLE; therefore, early diagnosis and prompt initiation of the treatment are crucial for renal and patient survival.
ISSN:1305-6441